

Editorial

Rheumatoid arthritis and osteoporosis

Rheumatoid arthritis is an inflammatory arthritis which changes the biomechanical properties of bones and leads to the alterations in bone components through the increased production of pro-inflammatory cytokines or by hormone mediated mechanisms (1-3).

In addition to traditional risk factors of osteoporosis, physical disability, inadequate treatment, and disease activity are also responsible factors of bone loss and osteoporosis in RA (4-6). Furthermore, disease duration, seropositivity for anti-cyclic citrullinated peptide antibody (anti-CCP) and rheumatoid factor (RF) have been shown to be associated with bone loss in RA (7, 8).

In this issue of journal Mobini et al. (9), in a study of 121 patients with RA, with age of 55.7 ± 10.1 years and mean disease duration of 10.1 ± 9.2 years found prevalence rates of femoral neck osteoporosis at 16.5% and lumbar spine osteoporosis at 23.1%. The data reported in this study indicated that only the age and body mass index (BMI) were significant associated factors of osteoporosis in RA and the contribution of other factors of osteoporosis including disease activity, disease duration, physical disability, and seropositivity for anti-CCP and RF in the development of osteoporosis was not significant.

The authors found their data comparable with the rate of osteoporosis reported from some other geographic regions but lower than other studies.

The inconsistent results across various published studies may be attributed to several parameters including the characteristics of the study population, disease activity of the study population, quality of treatment, criteria used for definition of low bone mass, site of BMD measurement, and duration of RA (4-6, 10-13). In addition, age, severity of joint involvement, glucocorticoid therapy can differently affect the rate of bone loss during the course of RA and result in variations in results (11, 12, 14).

The status of bone mass in RA has been investigated in some case-control and longitudinal studies (8, 10, 15-17). Bone mass in RA was shown to be lower compared with non-RA controls. Low bone mass was more evident in untreated disease and in patients with prolonged disease

duration particularly at the femoral neck region (8, 12, 14, 16). In some RA patients, even with active disease there was no reduction in bone mass and the patients' adequate bone mass was preserved particularly at the lumbar spine (14, 18).

It is known that low BMI and age are associated factors of osteoporosis in patients with RA as well as non-RA population. The main objective of studies which address osteoporosis in RA should be focused on the identification of reversible causes of osteoporosis such as disease activity, physical disability and elucidating their contribution in the development of osteoporosis for correction. These studies should include adequate number of patients for analysis, otherwise, the results may be underestimated. For example, the mentioned study required to include larger samples to confirm or deny a positive relationship between anti-CCP or RF with osteoporosis in RA. The most common causes of bone loss over the course of RA may be attributed to persistence of inflammation, adverse effects of cumulative dosages of glucocorticoid, physical disability due to joint destruction (4, 11). The appropriate treatment with anti-inflammatory drugs such as methotrexate with low-dose prednisolone can modulate the risk factors of osteoporosis and reduce the rate of bone loss and preserve further bone mass for later stages of RA (5, 6, 19). The improvement of hip synovitis with methotrexate or glucocorticoids has been shown to prevent femoral neck osteoporosis (13). On the other hand, cumulative dose of glucocorticoids may result in bone loss and osteoporosis in lumbar spine. Conversely, glucocorticoids therapy by suppression of inflammatory process and joint pain can improve the physical activity and exert disease modifying effect and preserve bone mass (8, 12). The traditional factors of bone loss in RA and their relationship with osteoporosis may be recognized by conducting a case-control study. However, the contribution of RA associated factors like anti-CCP, RF, disease activity and functional disability in bone mass loss and osteoporosis require longitudinal studies (6, 14).

Despite the several studies in this context, this issue requires further studies particularly in regard to bone mass protective effect of new treatment in RA.

Behzad Heidari ¹

Mohammad Reza Hassanjani Roushan ²

1. Department of Internal Medicine, Ayatollah Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran.

2. Infectious Diseases and Tropical Medicine Research Center, Babol university of Medical Sciences, Babol, Iran.

Email: researchbabol@gmail.com

Tel and Fax: 0098 111 2207924

References

1. Coulson KA, Reed G, Gilliam BE, Kremer JM, Pepmueller PH. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. *J Clin Rheumatol* 2009; 15: 155-60.
2. Mundy GR. Osteoporosis and inflammation. *Nutr Rev* 2007; 65: S147-51.
3. Oelzner P, Hein G. Inflammation and bone metabolism in rheumatoid arthritis. Pathogenetic viewpoints and therapeutic possibilities. *Med Klin (Munich)* 1997; 92: 607-14. [In German]
4. Cortet B, Flipo RM, Blanckaert F. Evaluation of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy. *Rev Rhum Engl Ed* 1997; 64: 451-8.
5. Lean RF, Buijs WC, Verbeek AL, et al. Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity. *Ann Rheum Dis* 1993; 52: 21-6.
6. Cortet B, Guyot MH, Solau E, et al. Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. *Clin Exp Rheumatol* 2000; 18: 683-90.
7. Guler H, Turhanoglu AD, Ozer B, Ozer C, Balci A. The relationship between anti-cyclic citrullinated peptide and bone mineral density and radiographic damage in patients with rheumatoid arthritis. *Scand J Rheumatol* 2008; 37: 337-42.
8. Heidari B, Jalali F. Bone densitometry in patients with Rheumatoid arthritis. *Acta Med Iran* 2005; 43: 99-104.
9. Mobini M, Kashi Z, Ghobadi far A. Prevalence and associated factors of osteoporosis in female patients with rheumatoid arthritis. *Caspian J Intern Med* 2012; 3: 421-4.
10. di Munno O, Mazzantini M, Sinigaglia L, et al. Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross-sectional study. *J Rheumatol* 2004; 31: 1305-9.
11. Hall GM, Spector TD, Griffin AJ, et al. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. *Arthritis Rheum* 1993; 36: 1510-16.
12. Engvall IL, Svensson B, Tengstrand B, et al. Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experience from a two-year randomized study. *Arthritis Res Ther* 2008; 10: R128.
13. Lodder MC, de Jong Z, Kostense PJ, et al. Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. *Ann Rheum Dis* 2004; 63: 1576-80.
14. Habib GS, Haj S. Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids. *Clin Rheumatol* 2005; 24: 129-33.
15. Haugeberg G, Ørstavik RE, Kvien TK. Effects of rheumatoid arthritis on bone. *Curr Opin Rheumatol* 2003; 15: 469-75.
16. Haugeberg G, Ørstavik RE, Uhlig T, et al. Bone loss in patients with rheumatoid arthritis: results from a population-based cohort of 366 patients followed up for two years. *Arthritis Rheum* 2002; 46: 1720-8.
17. Shankar S, Handa R, Aneja R, et al. Bone mineral density in Indian women with rheumatoid arthritis. *Rheumatol Int* 2009; 29: 377-81.
18. Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YP, et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. *Ann Rheum Dis* 2009; 68: 297-9.
19. Dolan AL, Moniz C, Abraha H, Pitt P. Does active treatment of rheumatoid arthritis limit disease-associated bone loss? *Rheumatology (Oxford)* 2002; 41: 1047-51.